Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00308945|
Recruitment Status : Completed
First Posted : March 30, 2006
Last Update Posted : January 17, 2008
|Condition or disease||Intervention/treatment||Phase|
|Open-Angle Glaucoma||Drug: travoprost 0.004% (drug) Drug: latanoprost 0.005% (drug)||Phase 4|
Background Glaucoma is a leading cause of blindness worldwide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increase in intraocular pressure (IOP). The actual therapeutic armamentarium for glaucoma includes miotics, beta-blockers, alpha-adrenergic agonists, oral and topical carbonic anhydrase inhibitors, and prostaglandin analogues, the latter being the latest addition to the armamentarium and the most potent topical IOP lowering drugs. Besides IOP, ocular blood flow alterations have been incriminated in glaucoma. Hence, it is of relevance to assess the effect of anti-glaucomatous drugs on ocular blood flow.
Rationale of the study Vasoactivity of topical drugs may be of prognostic relevance in glaucoma. There is very little information for a major class, the prostaglandin analogues with regard to this aspect. The vascular activity of two prostaglandin analogues, travoprost 0.004% and latanoprost 0.005%, which are already on the Swiss market, will be tested.
Study objectives Primary Objective: To assess the effect of two prostaglandin analogues, travoprost 0.004% and latanoprost 0.005% on choroidal blood flow in primary open-angle glaucoma patients.
Secondary Objective: To assess the effect of travoprost 0.004% and latanoprost 0.005% on retinal vascular diameter in primary open-angle glaucoma patients.
Investigational plan Primary open-angle-glaucoma patients will be assessed regarding inclusion/exclusion criteria. After a washout of current topical medication (beta-blockers and prostaglandin analogues: 4 weeks; topical carbonic anhydrase inhibitors and alpha-agonists: 2 weeks; Pilocarpine: 1 week), half of the patients (17 patients) will be treated with travoprost 0.004% for 1 month while the other 17 patients will be treated with latanoprost 0.005% for the same duration. Efficacy and safety variables will be assessed at baseline, after 2 weeks, and after 1 month of treatment. After this first period, the patients will be washed out for 4 weeks and baseline efficacy and safety parameters will be obtained. Afterwards, the patients will be treated with the other compound. Again, efficacy and safety variables will be assessed after 2 weeks and after 1 month of treatment.
Design Single center, randomized, double masked 2-way cross-over design. Randomization The patients will be divided in two groups, and each group will alternatively be started with either travoprost 0.004% or latanoprost 0.005%. Recruitment and management will be carried out by a study nurse masked to baseline blood flow measurement results. Masking and randomization procedures will be entrusted to Alcon PHARMACEUTICAL AG. The drug products for this study will be prepared by the following procedure: Each product will be labeled during independent labeling operations. For this study four different products will have to be labeled: travatan medicin A, travatan medicin B, xalatan medicin A and xalatan medicin B. Each labeling operation will start and end with a line clearance procedure and each labeling order will be 100% inspected by a person that is independent from the person who will do the labeling. On each label the patient number will indicated. The labeling order will be initiated by using the randomization list that indicates which product has to be labeled for which patient. The randomization sequence will be pulled from a uniform distribution with an arbitrary seed (Randomization Performed with SAS 8.2 on NT using RANUNI [seed]). During each independent labeling operation also the disclosure labels will be provided with the same patient number than indicated on the open label. After release of each independent labeling procedure, the assembly of the packaging of two carton boxes in an assembly carton box will start for each patient. The assembly box will also be also labeled with patient number/investigator number and protocol number. Release of the labeled samples will always be done by an independent QA department.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||February 2005|
|Actual Study Completion Date :||February 2005|
cross-over comparison of two substances
Drug: latanoprost 0.005% (drug)
local drop application
Drug: travoprost 0.004% (drug)
local drop application
- effect on choroidal blood flow [ Time Frame: baseline - 2 weeks - 4 weeks ]
- effect on retinal vascular diameter [ Time Frame: baseline - 2 weeks - 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00308945
|University Eye Clinic|
|Basel, BS, Switzerland, 4031|
|Principal Investigator:||Selim Orgul, MD||University Eye Clinic Basel|